| John C Rhinehart, CRNA | |
|
355 N Main St, Kanab, UT 84741-3260 | |
| (928) 812-2025 | |
| Not Available |
| Full Name | John C Rhinehart |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 355 N Main St, Kanab, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730149659 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | CRNA0369 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| John C Rhinehart, CRNA Po Box 152, Kanab, UT 84741-0152 Ph: (928) 812-2025 | John C Rhinehart, CRNA 355 N Main St, Kanab, UT 84741-3260 Ph: (928) 812-2025 |
News Archive
A team of data scientists, physicians, and engineers across the Mount Sinai Health System has come together to launch STOP COVID NYC, a web-based app to capture the symptoms and spread of COVID-19 in New York City-currently the epicenter of the nation's largest outbreak.
Vita-Tech International, Inc. has donated one ton of vitamins to Conakry, Guinea, West Africa, to support nutritionally disadvantaged populations in polio treatment centers throughout the country, as well as rural villages in the area surrounding Conakry. "This donation will provide nutritional support for hundreds of people for a long period, with follow-up shipments planned to insure continuity of care," according to Tom Tierney, President of Vita-Tech.
An increasing number of obese adolescents, particularly females, are undergoing gastric bypass surgery. Yet a case study presented Sunday, Oct. 3, at the American Academy of Pediatrics (AAP) National Conference and Exhibition in San Francisco, highlights the possible link between gastric bypass surgery in adolescent girls and an increased risk for neural tube defects, which can lead to varying degrees of disability such as paralysis and mental retardation due to damage to the nervous system, in their future children.
BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.
› Verified 7 days ago
Mr. Weston Marshall Swindlehurst, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 355 North Main St, Anesthesia Dept, Kanab, UT 84741 Phone: 435-644-5811 |